Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 11/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 11/20 | 0.54 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.52 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.52 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12101034 | 0.91 | CHRM2 (0.53) | CHRM2CHRM3SCD5ACKR3HPGDS | |
| SCHEMBL2141128 | 0.87 | CHRM2 (0.58) | CHRM2CHRM3HTR2CEPHX2 | |
| SCHEMBL2143363 | 0.85 | CHRM2 (0.61) | CHRM2CHRM3SCD5EPHX2PIK3CA | |
| SCHEMBL6912745 | 0.84 | ACKR3 (0.66) | SCD5ACKR3HPGDSHTR2C | |
| SCHEMBL1246052 | 0.83 | CHRM2 (0.64) | CHRM2CHRM3SCD5EPHX2PIK3CA | |
| SCHEMBL1247151 | 0.83 | CHRM2 (0.64) | CHRM2CHRM3SCD5PIK3CAMTOR | |
| SCHEMBL17328261 | 0.82 | EPHX2 (0.58) | CHRM2CHRM3SCD5EPHX2PIK3CA | |
| SCHEMBL2140846 | 0.82 | CHRM2 (0.55) | CHRM2CHRM3HTR2C | |
| SCHEMBL31687490 | 0.81 | ACKR3 (0.63) | SCD5ACKR3HPGDSHTR2C | |
| SCHEMBL17328213 | 0.81 | CHRM2 (0.56) | CHRM2CHRM3SCD5EPHX2PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629271-B2 | Compounds | ASTRAZENECA AB (GB) | 2014-01-14 | — | — | US | disclosed |
| US-8629271-B2 | Compounds | ASTRAZENECA AB (GB) | 2014-01-14 | — | — | US | disclosed |
| US-8629271-B2 | Compounds | ASTRAZENECA AB (GB) | 2014-01-14 | — | — | US | disclosed |
| US-20120322788-A1 | Compouds | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2012-12-20 | — | — | US | disclosed |
| US-20120322788-A1 | Compouds | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2012-12-20 | — | — | US | disclosed |
| US-20120322788-A1 | Compouds | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2012-12-20 | — | — | US | disclosed |
| EP-2242759-B1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2012-09-12 | — | — | EP | disclosed |
| US-8148373-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| US-8148373-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| US-8148373-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| EP-2242759-A1 | COMPOUNDS | AstraZeneca AB (SE) | 2010-10-27 | — | — | EP | disclosed |
| US-20090298807-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| US-20090298807-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| US-20090298807-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| WO-2009098448-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009098448-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322788-A1 | Compouds | PKD1, SBDS, ABCB11 | CHRM2 3668/4885CHRM3 4265/4885SCD5 2283/4885 |
| US-20090298807-A1 | Compounds | PKD1, SLC10A1, ABCB11 | CHRM2 2419/4885CHRM3 2714/4885SCD5 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.